|20.78||+0.2700||+1.32%||Vol 17.57K||1Y Perf 64.04%|
|Apr 23rd, 2021 10:51 DELAYED|
|- -%||- -|
|Target Price||30.17||Analyst Rating||Strong Buy 1.00|
|Potential %||44.98||Finscreener Ranking||★★★+ 52.43|
|Insiders Trans % 3/6/12 mo.||-100/-100/-63||Value Ranking||★ 41.06|
|Insiders Value % 3/6/12 mo.||-100/-100/-77||Growth Ranking||★★★★ 60.00|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-68||Income Ranking||— -|
|Market Cap||673.50M||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||69.64||Earnings Date||5th May 2021|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||-0.43|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||142.92K|
|Avg. Monthly Volume||194.40K|
|Avg. Quarterly Volume||248.74K|
Harpoon Therapeutics Inc. (NASDAQ: HARP) stock closed at 20.51 per share at the end of the most recent trading day (a 3.85% change compared to the prior day closing price) with a volume of 213.83K shares and market capitalization of 673.50M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 77 people. Harpoon Therapeutics Inc. CEO is Gerald McMahon.
The one-year performance of Harpoon Therapeutics Inc. stock is 64.04%, while year-to-date (YTD) performance is 23.48%. HARP stock has a five-year performance of %. Its 52-week range is between 10.55 and 25.24, which gives HARP stock a 52-week price range ratio of 69.64%
Harpoon Therapeutics Inc. currently has a PE ratio of -10.10, a price-to-book (PB) ratio of 12.04, a price-to-sale (PS) ratio of 43.90, a price to cashflow ratio of 12.20, a PEG ratio of 2.32, a ROA of -27.43%, a ROC of -55.46% and a ROE of -63.81%. The company’s profit margin is -%, its EBITDA margin is -410.00%, and its revenue ttm is $14.15 Million , which makes it $0.44 revenue per share.
Of the last four earnings reports from Harpoon Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.43 for the next earnings report. Harpoon Therapeutics Inc.’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Harpoon Therapeutics Inc. is Strong Buy (1), with a target price of $30.17, which is +44.98% compared to the current price. The earnings rating for Harpoon Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Harpoon Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Harpoon Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.31, ATR14 : 1.68, CCI20 : -34.02, Chaikin Money Flow : 0.22, MACD : 0.12, Money Flow Index : 59.14, ROC : -6.13, RSI : 46.26, STOCH (14,3) : 40.48, STOCH RSI : 1.00, UO : 57.64, Williams %R : -59.52), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Harpoon Therapeutics Inc. in the last 12-months were: Georgia L. Erbez (Buy at a value of $101 178), Georgia L. Erbez (Option Excercise at a value of $53 000), Holger Wesche (Option Excercise at a value of $24 000), Holger Wesche (Sold 40 000 shares of value $691 242 ), Natalie Sacks (Option Excercise at a value of $15 578), Natalie Sacks (Sold 7 348 shares of value $92 780 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.